A Phase 3, Double-Blind, Placebo-Controlled Study of Quizartinib (AC220) Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 tp 75 Years Old with Newly Diagnosed FLT3-ITD

Grants and Contracts Details

StatusFinished
Effective start/end date9/21/1610/6/23

Funding

  • Daiichi Sankyo Incorporated: $147,866.00